Development of renal disease in people at high cardiovascular risk: Results of the HOPE randomized study

Journal of the American Society of Nephrology

Volumn 14, Issue 3, 2003, Pages 641-647

  Mann, Johannes F E ^a,c,d   Gerstein, Hertzel C ^b   Yi, Qi Long ^b   Lonn, Eva M ^b   Hoogwerf, Byron J ^a   Rashkow, Andrew ^a   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF MUNICH   (Germany)

^d Ger Inst High Blood Pressure Res   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIURETIC AGENT; RAMIPRIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE COURSE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT;

EID: 0037373244     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000051594.21922.99     Document Type: Article

References (13)

1. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin dependent diabetes mellitus: A systematic overview of the literature. Arch Int Med 157: 1413-1418, 1997
2. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346: 1080-1084, 1995
3. Kasiske BL: Relationship between vascular disease and age- associated changes in the human kidney. Kidney Int 31: 1153-1159, 1987
4. Hall WD: Abnormalities of kidney function as a cause and a consequence of cardiovascular disease (Review). Am J Med Sci 317: 176-182, 1999
5. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic uremia. J Am Soc Nephrol 10: 1053-1058, 1999
6. The HOPE investigators: The HOPE (Heart Outcomes and Prevention Evaluation) study: the design of a large, simple randomized trial of an ACE inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 12: 127-137, 1996
7. The HOPE investigators: Effects of an ACE inhibitor, ramipril, on cardiovascular events in high risk patients. New Engl J Med 342: 145-153, 2000
8. The HOPE investigators: Vitamin E supplementation and cardiovascular events in high risk patients. New Engl J Med 342: 154-160, 2000
9. The HOPE investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MicroHOPE substudy. Lancet 355: 253-259, 2000
10. Gerstein HC, Mann JFE, Qilong Y, Zinman B, Dineen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and cardiovascular events, death and heart failure in diabetic and non-diabetic individuals. J Am Med Ass 286: 421-426, 2001
11. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Int Med 134: 629-636, 2001
12. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Ponticelli C, Ritz E, Zucchelli P: Effects of the ACE inhibitor benazepril on the progression of chronic renal insufficiency. New Engl J Med 334: 939-945, 1996
13. Ruggenenti P, Perna P, Gherardi G, Gaspari F, Benini F, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 352: 1252-1256, 1998